Robert W. Baird reaffirmed their hold rating on shares of LHC Group (NASDAQ:LHCG) in a research note issued to investors on Friday morning. They currently have a $69.00 target price on the health services provider’s stock.

A number of other research firms also recently issued reports on LHCG. Royal Bank Of Canada lifted their price target on LHC Group from $70.00 to $81.00 and gave the company an outperform rating in a research note on Tuesday, November 7th. Zacks Investment Research downgraded LHC Group from a buy rating to a hold rating in a research note on Wednesday, October 4th. BidaskClub upgraded LHC Group from a hold rating to a buy rating in a research note on Friday, August 18th. Bank of America Corporation began coverage on LHC Group in a research note on Monday, August 21st. They issued a buy rating and a $76.00 target price on the stock. Finally, Craig Hallum restated a buy rating and issued a $80.00 target price (up previously from $67.00) on shares of LHC Group in a research note on Tuesday, November 7th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. LHC Group currently has an average rating of Buy and an average price target of $76.40.

Shares of LHC Group (NASDAQ:LHCG) traded down $1.26 on Friday, reaching $66.26. The company’s stock had a trading volume of 182,600 shares, compared to its average volume of 162,560. LHC Group has a 52-week low of $41.66 and a 52-week high of $76.14. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.77 and a quick ratio of 1.75. The firm has a market cap of $1,211.23, a P/E ratio of 28.44, a PEG ratio of 1.96 and a beta of 0.70.

LHC Group (NASDAQ:LHCG) last issued its earnings results on Monday, November 6th. The health services provider reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. The business had revenue of $272.90 million during the quarter, compared to analyst estimates of $265.35 million. LHC Group had a return on equity of 9.52% and a net margin of 4.09%. The firm’s revenue was up 18.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.54 EPS. equities research analysts forecast that LHC Group will post 2.4 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “LHC Group’s (LHCG) Hold Rating Reaffirmed at Robert W. Baird” was reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/lhc-groups-lhcg-hold-rating-reaffirmed-at-robert-w-baird/1698671.html.

In related news, COO Donald Dwayne Stelly sold 2,650 shares of the stock in a transaction on Friday, September 8th. The stock was sold at an average price of $65.34, for a total value of $173,151.00. Following the transaction, the chief operating officer now owns 109,235 shares of the company’s stock, valued at $7,137,414.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 14.80% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Federated Investors Inc. PA boosted its position in LHC Group by 4.2% during the second quarter. Federated Investors Inc. PA now owns 1,622 shares of the health services provider’s stock valued at $110,000 after buying an additional 66 shares during the period. Acrospire Investment Management LLC boosted its position in LHC Group by 30.8% during the second quarter. Acrospire Investment Management LLC now owns 1,700 shares of the health services provider’s stock valued at $115,000 after buying an additional 400 shares during the period. Cubist Systematic Strategies LLC boosted its position in LHC Group by 758.0% during the second quarter. Cubist Systematic Strategies LLC now owns 1,716 shares of the health services provider’s stock valued at $116,000 after buying an additional 1,516 shares during the period. First Mercantile Trust Co. purchased a new stake in LHC Group during the second quarter valued at about $147,000. Finally, SG Americas Securities LLC purchased a new stake in LHC Group during the third quarter valued at about $163,000. Institutional investors and hedge funds own 87.32% of the company’s stock.

LHC Group Company Profile

LHC Group, Inc is a holding company. The Company provides post-acute healthcare services to patients through its home nursing agencies, hospice agencies, community-based services agencies and long-term acute care hospitals (LTACHs). The Company operates through four segments: home health services, hospice services, community-based services and facility-based services.

Analyst Recommendations for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with Analyst Ratings Network's FREE daily email newsletter.